Avicanna Inc · TSX:AVCN

Avicanna — Investor Presentation (November 2026)

14 slides from Avicanna's investor presentation, November 2026

  1. Slide 1: A Biopharmaceutical Leader in Cannabinoid-Based Medicine

    A Biopharmaceutical Leader in Cannabinoid-Based Medicine Q4 2026 TSX: AVCN OTCQB: AVCNF FSE: 0NN avicanna.com

  2. Slide 2: Integrated Cannabinoid-Based Biopharmaceutical Platform

    Integrated Cannabinoid-Based Biopharmaceutical Platform An integrated commercial and scientific platform combining proprietary products, nationwide medical distribution, pharmaceutical development and international supply capabilities. Commercial & Medical Platform • 4 integrated commercial-stage bu

  3. Slide 3: RHO Phyto | Proprietary Medical Cannabis Portfolio

    RHO Phyto | Proprietary Medical Cannabis Portfolio Pharmaceutical-grade cannabinoid formulations Standardized cannabinoid formulations across multiple delivery systems Proprietary drug delivery systems designed to enhance bioavailability and dosing precision Supported by pre-clinical, clinical, and

  4. Slide 4: Introducing QUIX Rapid Onset Portfolio

    Introducing QUIX Rapid Onset Portfolio Designed for faster onset, enhanced bioavailability and next-generation cannabinoid products QUIX is Avicanna’s proprietary nano-emulsion-based drug delivery technology designed to address cannabinoid formulation challenges, including delayed onset and variable

  5. Slide 5: MyMedi.ca | Medical Cannabis Care Platform

    MyMedi.ca | Medical Cannabis Care Platform Avicanna’s proprietary, pharmacist-led platform connecting patients, practitioners and payers A nationwide medical cannabis care platform that supports patients from registration through ongoing treatment, combining a curated formulary, pharmacist- led clin

  6. Slide 6: MyMedi.ca | Nationwide Medical & Commercial Infrastructure

    MyMedi.ca | Nationwide Medical & Commercial Infrastructure A proprietary platform enabling patient access, real-world evidence, and commercialization of cannabinoid-based therapies Strategic Value • Direct engagement with patients, prescribers, and payers • Real-world evidence generation platform •

  7. Slide 7: Six Integrated Pillars of Medical Cannabis Care

    Six Integrated Pillars of Medical Cannabis Care A complete platform designed around the patient journey and the healthcare ecosystem 01 02 03 Digital Pharmacy & E- Patient Support & Portfolio & Formulary Commerce Clinical Services 200+ products • 35+ brands Registration • ordering • CRM Pharmacist-l

  8. Slide 8: Pharmaceutical Pipeline | Status

    Pharmaceutical Pipeline | Status Avicanna programs by development stage, with completed and ongoing work Program Formulation Preclinical RWE / Clinical Approved Completed Underway Observational Deep Tissue Gel Formulation; in vitro studies; observational study MSK pain Phase II RCT design (N≈115) CB

  9. Slide 9: Global Commercial Platform | International Expansion

    Global Commercial Platform | International Expansion Expanding cannabinoid-based pharmaceutical and medical products across international markets Commercial Presence and Potential • Historical commercial exports to 24 countries across six continents • Scalable platform supported by integrated API an

  10. Slide 10: Established Scientific Platform & Institutional Validation

    Established Scientific Platform & Institutional Validation Supporting the development of evidence-based cannabinoid therapeutics Scientific Platform • Proprietary formulation and delivery technologies • Clinical and pre-clinical research programs 60+ 3 Proprietary Ongoing Clinical Trials • Real-worl

  11. Slide 11: Financial Highlights | Q3 2026

    Financial Highlights | Q3 2026 Positive Adjusted EBITDA, stable margins and a leaner cost structure $5.73M 50.9% $0.22M 27% Q3 2026 revenue Gross margin (+1.7 pts Adjusted EBITDA (+$1.01M G&A reduction YoY YoY) YoY) Q3 2026 Performance Cost Discipline & Working Capital • Revenue of $5.73M; $18.05M f

  12. Slide 12: Management and Board of Directors

    Management and Board of Directors Senior Management Team Board of Directors AA Aras Azadian AA Aras Azadian Founder and CEO Founder and CEO NH Nick Hilborn LM Lisa McCormack Chief Financial Officer Independent Director SK Stephen Kim OK Ozgur Kilic Chief Legal Officer & General Counsel Independent D

  13. Slide 13: Investment Highlights

    Investment Highlights 01 02 03 Financial Inflection Commercial Scale Differentiated IP Positive Q3 Adjusted EBITDA and 68 proprietary SKUs and 178 Canadian QUIX launched commercially; PwdRx materially reduced operating commercial listings development advancing expenses 04 05 06 Integrated Medical Pl

  14. Slide 14: Thank You

    Thank You Q4 2026 TSX: AVCN OTCQB: AVCNF FSE: 0NN avicanna.com info@avicanna.com

Avicanna — Investor Presentation (November 2026) on 6ix